Long-term safety of satralizumab in neuromyelitis optica spectrum disorder: results from the open-label extension periods of SAkuraSky and SAkuraStar

被引：0

作者：

Greenberg, B. M. ^{[1
]}

de Seze, J. ^{[2
]}

Saiz, A. ^{[3
,4
]}

Yamamura, T. ^{[5
]}

Yeaman, M. ^{[6
]}

Marcillat, C. ^{[7
]}

Kou, X. ^{[7
]}

Weber, K. ^{[7
]}

Blondeau, K. ^{[7
]}

Weinshenker, B. G. ^{[8
]}

Patti, F. ^{[9
,10
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[2] Hop Hautepierre, Strasbourg, France

[3] Hosp Clin Barcelona, Serv Neurol, Barcelona, Spain

[4] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

[5] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo, Japan

[6] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA

[7] F Hoffmann La Roche Ltd, Basel, Switzerland

[8] Mayo Clin, Rochester, MN USA

[9] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Catania, Italy

[10] Multiple Sclerosis Ctr AOU Policlin G Rodolico Sa, Catania, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P023

引用

页码：147 / 148

页数：2